Clinical Scorecard: Johannes Joseph van Rood: A Trailblazer in Immunogenetics (April 7, 1926 – July 21, 2017)
At a Glance
Category
Detail
Condition
Immunogenetics and hematopoietic cell transplantation
Key Mechanisms
HLA system serotyping, anti-leukocyte antibodies, non-inherited maternal antigens, H-Y-associated antigens
Target Population
Patients requiring blood transfusion and hematopoietic cell transplantation
Care Setting
Hospital immunohematology and transplant biology departments
Key Highlights
Pioneered use of computers for HLA-serotyping data analysis in early immunogenetics research.
Discovered anti-leukocyte antibodies in parous women, linking pregnancy history to transfusion reactions.
Co-founded major international organizations facilitating bone marrow donor registries and transplant collaboration (Eurotransplant, EBMT, CIBMTR, BMDW, WMDA).
Guideline-Based Recommendations
Diagnosis
Utilize leukocyte typing methods for HLA system characterization in transplant candidates.
Consider patient pregnancy history when evaluating transfusion reactions due to anti-leukocyte antibodies.
Management
Incorporate knowledge of non-inherited maternal antigens and H-Y-associated antigens in donor selection to improve transplant outcomes.
Leverage international donor registries to optimize hematopoietic cell transplantation matching.
Monitoring & Follow-up
Monitor for immune reactions post-transfusion or transplantation related to HLA incompatibilities.
Risks
Risk of transfusion reactions in multiparous women due to alloimmunization.
Potential graft rejection or complications from mismatched HLA antigens.
Patient & Prescribing Data
Patients undergoing blood transfusion and hematopoietic cell transplantation
Understanding of HLA compatibility and antibody presence guides donor selection and reduces adverse immune reactions.
Clinical Best Practices
Employ detailed HLA typing and antibody screening prior to transfusion or transplantation.
Utilize international collaboration and donor registries to identify optimal matches.
Maintain a clinician-scientist approach to integrate laboratory findings with patient care.
The Temple Lung Center conducts one of the most comprehensive lung disease clinical trials programs in the country. Our advancements in basic, translational and clinical research are changing lung disease treatment. By pioneering effective therapies, we bring hope to patients with serious and debilitating lung diseases.
